Summary
Starting July 1, 2026, Medicare will run a temporary pilot called the Medicare GLP-1 Bridge that offers certain beneficiaries GLP‑1 weight‑loss medications for a flat $50 monthly copay. The program runs through Dec. 31, 2027, and is intended as a short-term bridge to a possible longer-term approach after 2027.
What the program covers
– Eligible drugs: GLP‑1 medications approved for weight loss, including oral and injectable Wegovy formulations, Zepbound’s KwikPen formulation, and the Foundayo pill.
– Enrollment: You must be enrolled in a Medicare Part D plan to participate in the Bridge.
Who qualifies
– Primary eligibility is based on body mass index (BMI) and certain health conditions.
– Automatic qualification with BMI ≥ 35. People with BMI ≥ 27 may qualify if they have a qualifying condition such as heart disease or prediabetes.
– Because recent CDC data show about 40% of U.S. adults have obesity (BMI ≥ 30), a substantial number of Medicare beneficiaries could meet BMI-based criteria.
How the program works
– Even though Part D enrollment is required, the Bridge uses a centralized processing system run by a CMS contractor (Humana) instead of each beneficiary’s usual Part D plan.
– Prescribers submit prior authorization requests to the centralized system; prescribers do not have to be enrolled Medicare providers to submit requests.
– If approved, the beneficiary pays a flat $50 copay at the pharmacy for the weight‑loss indication.
Benefits
– A predictable $50 monthly copay may make GLP‑1s affordable for people who face current cash prices that can range roughly $149–$699 per month depending on drug and dose.
– The copay is flat and does not increase with higher doses, which matters because higher doses are often needed to maintain weight loss.
Drawbacks and limits
– The $50 copay does not count toward the Part D deductible or the annual out‑of‑pocket cap for prescription drugs.
– The program is temporary and ends on Dec. 31, 2027; stopping GLP‑1 therapy often leads to weight regain, so the limited duration is a concern.
– Beneficiaries receiving the low‑income subsidy (Medicare Extra Help) cannot apply that assistance to drugs covered by the Bridge; those accustomed to $5–$10 copays may find $50 unaffordable.
– If a GLP‑1 is prescribed for other covered indications (Type 2 diabetes, cardiovascular risk reduction, sleep apnea, etc.), it will remain under the patient’s regular Part D plan and could cost more than $50.
Continuity for current users
– People already taking a GLP‑1 for weight loss may qualify for the Bridge if their prescriber attests they met the clinical criteria at therapy start (for example, met a BMI threshold before treatment lowered weight).
What happens after 2027
– The administration had proposed a two‑step plan: a short Bridge followed by a longer insurer‑focused program. A voluntary insurer program did not attract enough participation, so CMS extended the Bridge to 18 months.
– CMS has not released full cost estimates. Analysts previously projected that an insurer‑shifted model would cost insurers billions in year one, and the Bridge will still be expensive for Medicare because it subsidizes these drug costs. Final cost depends on uptake; millions could be clinically eligible.
Additional notes and next steps
– Cash prices listed on discount sites vary by dose; higher doses can cost substantially more than introductory pricing.
– The Bridge’s $50 copay applies only to weight‑loss indications; the same drug may cost differently under other diagnoses.
– If you’re on Medicare and interested in GLP‑1 therapy for weight loss, check with your Part D plan and your prescriber about prior authorization procedures and whether you meet the Bridge clinical criteria.